DE2915254C2 - - Google Patents
Info
- Publication number
- DE2915254C2 DE2915254C2 DE2915254A DE2915254A DE2915254C2 DE 2915254 C2 DE2915254 C2 DE 2915254C2 DE 2915254 A DE2915254 A DE 2915254A DE 2915254 A DE2915254 A DE 2915254A DE 2915254 C2 DE2915254 C2 DE 2915254C2
- Authority
- DE
- Germany
- Prior art keywords
- deoxyuridine
- bromovinyl
- virus
- compounds
- iodovinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 35
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 claims description 18
- LOLNFJHUEIDGNH-PIXDULNESA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(e)-2-iodoethenyl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\I)=C1 LOLNFJHUEIDGNH-PIXDULNESA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 8
- 241000700584 Simplexvirus Species 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 241000700605 Viruses Species 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 19
- 230000000840 anti-viral effect Effects 0.000 description 18
- -1 2-iodovinyl Chemical group 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 229920002554 vinyl polymer Polymers 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 208000009889 Herpes Simplex Diseases 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- KTZDXHJATZVCLY-OWOJBTEDSA-N 5-[(e)-2-iodoethenyl]-1h-pyrimidine-2,4-dione Chemical compound I\C=C\C1=CNC(=O)NC1=O KTZDXHJATZVCLY-OWOJBTEDSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000001399 anti-metabolic effect Effects 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000002348 vinylic group Chemical group 0.000 description 4
- ZRYZBEQILKESAW-UHFFFAOYSA-N 5-ethenyl-1h-pyrimidine-2,4-dione Chemical compound C=CC1=CNC(=O)NC1=O ZRYZBEQILKESAW-UHFFFAOYSA-N 0.000 description 3
- CDEURGJCGCHYFH-DJLDLDEBSA-N 5-ethynyl-2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-DJLDLDEBSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- FQRIBMHYAICHAB-DJLDLDEBSA-N 5-(1-chloroethenyl)-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(Cl)=C)=C1 FQRIBMHYAICHAB-DJLDLDEBSA-N 0.000 description 2
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 2
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 1
- PDWIQYODPROSQH-PYHARJCCSA-N 2-deoxy-D-ribofuranose Chemical compound OC[C@H]1OC(O)C[C@@H]1O PDWIQYODPROSQH-PYHARJCCSA-N 0.000 description 1
- YAAQOXBNCODRSI-DJLDLDEBSA-N 5-ethenyl-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=C)=C1 YAAQOXBNCODRSI-DJLDLDEBSA-N 0.000 description 1
- OHAMXGZMZZWRCA-UHFFFAOYSA-N 5-formyluracil Chemical compound OC1=NC=C(C=O)C(O)=N1 OHAMXGZMZZWRCA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
NMR: ε (d₆DMSO): 11,2 (2-H, bd, N-H's), 7,7 (1-H, d, H-6, J=6 Hz) 7,3 (1-H, E-(trans)vinylisches H-2′, J=13 Hz), 6,8 ppm (1-H, E-(trans)vinylisches H-1′, J=13 Hz).
UV: λmax 290 nm (ε, 9,930), 251 nm (ε, 17,500), λmin 275 nm (ε, 8,280) bei pH-1, gmax 305 (ε, 11,400), 267 nm (ε, 15,400), λmin 290 nm (ε, 10,500) bei pH-13.
NMR: δ (CCl₄): 8,05 (1-H, s, H-6), 6,83 (2-H, s, vinylische H's), 0,38, 0,30 ppm (18H, 2s, Me₃Si- an -2-O- und 4-O-) (Me₄Si externer Standard).
NMR: δ (CDCl₃): 8,28 (1-H, s, N-H), 7,94 (4-H, d, aromatische H's), 7,41 (1-H, s, H-6), 7,26 (5-H, m, aromatische H's und E-vinylisches H-2′′), 6,40 (1-H, t, H-1′), 6,08 (1-H, d, E-vinylisches H-1′′, J=13 Hz), 5,62 (1-H, d, H-3′), 4,72 (2-H, dd, H-5′), 4,54 (1-H, m, H-4′), 2,7 (2-H, bm, H-2′), 2,42 ppm (6-H, s, CH₃′s).
UV: max 244 nm (ε, 37,400), 286 nm (sh) (ε, 8,550) in Ethanol.
Schmp. 186-188° (Zers.).
NMR: δ (d₆DMSO): 11,24 (1=H, s, N-H), 8,08 (1-H, s, H-6), 7,24 (1-H, d, E-vinylisches H-2′′), 6,81 (1-H, d, E-vinylisches H-1′′, J=13 Hz), 6,10 (1-H, t, H-1), 5,18 (1-H, d, OH-3′), 5,02 (1-H, t, OH-5′), 4,22 (1-H, m, H-3′), 3,78 (1-H, m, H-4′), 3,58 (2-H, m, H-5), 2,12 ppm (2-H, m, H-2′).
UV: λmax 253 nm (ε, 13,100), 295 nm (ε, 10,300), λmin 274 nm (7,500) in Ethanol.
NMR: δ (d₆DMSO): 11,1 (2-H, bd, N-H′s), 7,7 (1-H, d, H-6, J=6 Hz), 7,2 ppm (2-H's, vinylische H's)
UV: λmax 294 nm (ε, 9,900), 250 nm (ε, 15,200), λmin 278 nm (ε, 9,250) bei pH-1, λmax 310 nm (ε, 12,200), λmax 262 nm (ε, 15,850), λmin 290 nm (ε, 10,050) bei pH-13.
NMR: δ (CCl₄): 8,0 (1-H, s, H-6), 7,2 (1-H, d, E-(trans)vinylisches H-2′, J=15 Hz), 6,8 (1-H, d, E-(trans)vinylisches H-1′, J=15 Hz), 0,4, 0,3 ppm (18-H, 2s, Me₃Si- an 2-O- und 4-O-).
NMR: δ (CDCl₃): 8,5 (1-H, bs, N-H), 6,45 ppm (2-H, m, H-1′ und E-(trans)vinylisches H-1′′).
UV: λmax 242 nm (ε, 33,950), λmax 295 nm (ε, 9,650), λmin 272 nm (ε, 7,850) in Ethanol.
NMR: δ (d₆DMSO): 11,6 (1-H, bs, N-H), 8,08 (1-H, s, H-6), 7,17 (2-H, s, vinylische H's), 6,14 ppm (1-H, H-1′, J=6 Hz).
UV: gmax 250 nm (ε, 14,100), λmax 295 nm (ε, 11,450), λmin 275 nm (ε, 8,450) in Ethanol.
Schmp. 108-110°C (Z.).
NMR: δ (d₆DMSO): 11,2 (1-H, bs, N-H), 8,37 (1-H, s, H-6), 6,43 (1-H, s, vinylisches H, trans zum heterocyclischen Ring), 6,18 (1-H, t, H-1′), 5,54 (1-H, s, vinylisches H, cis zum heterocyclischen Ring), 5,1 (2-H, bs, O-H), 4,25 (1-H, m, H-3′), 3,86 (1-H, m, H-4′), 3,70 (2-H, m, H-5′), 2,17 ppm (2-H, m, H-2′).
UV: λmax 234 nm (ε, 9,370), 282 nm (ε, 10,500), λmin 259 nm (ε, 6,550) bei pH 6.
Claims (4)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB16158/78A GB1601020A (en) | 1978-04-24 | 1978-04-24 | 2'-deoxy-5 (2-halogenovinyl)-uridines |
Publications (2)
Publication Number | Publication Date |
---|---|
DE2915254A1 DE2915254A1 (de) | 1979-11-15 |
DE2915254C2 true DE2915254C2 (de) | 1990-07-12 |
Family
ID=10072234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19792915254 Granted DE2915254A1 (de) | 1978-04-24 | 1979-04-14 | Neue chemische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel mit antiviraler wirkung |
Country Status (11)
Country | Link |
---|---|
US (1) | US4424211A (de) |
JP (1) | JPS554364A (de) |
BE (1) | BE875773A (de) |
CA (1) | CA1117108A (de) |
CH (1) | CH643273A5 (de) |
DE (1) | DE2915254A1 (de) |
FR (1) | FR2432526A1 (de) |
GB (1) | GB1601020A (de) |
IT (1) | IT1165954B (de) |
NL (1) | NL192793C (de) |
SE (1) | SE445832B (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5687599A (en) * | 1979-12-19 | 1981-07-16 | Yamasa Shoyu Co Ltd | E 55 22halogenovinyl arabinofuranosyluracil and its preparation |
US4383990A (en) * | 1980-10-01 | 1983-05-17 | Beecham Group Limited | Antiviral agents, their preparation and use |
EP0060099A1 (de) * | 1981-03-11 | 1982-09-15 | Beecham Group Plc | Antivirale Verbindungen, ihre Herstellung und Verwendung |
NZ199764A (en) * | 1981-03-20 | 1984-08-24 | Beecham Group Plc | 5-(2-halogenovinyl)-2'-deoxyuridine derivatives and pharmaceutical compositions |
EP0072137A1 (de) * | 1981-08-01 | 1983-02-16 | Beecham Group Plc | Antivirale Deoxyuridin-Derivate |
HU183567B (en) * | 1981-09-07 | 1984-05-28 | Mta Koezponti Kemiai Kutato In | Process for preparing /e/-5-/2-bromo-vinyl/-uridine and derivatives thereof |
EP0082667A1 (de) * | 1981-12-18 | 1983-06-29 | Beecham Group Plc | Pharmazeutische Zusammensetzungen |
EP0088501B1 (de) * | 1982-02-12 | 1986-04-16 | United Kingdom Atomic Energy Authority | Laser-Rohrschweiss- bzw. -Schneidgerät |
EP0095292A1 (de) * | 1982-05-22 | 1983-11-30 | Beecham Group Plc | 5-(2-Halovinyl)-2'-deoxyuridin-Derivate, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Anwendung bei der Behandlung von viralen Infektionen |
EP0095294A1 (de) * | 1982-05-22 | 1983-11-30 | Beecham Group Plc | Deoxyuridin-Derivate, ihre Herstellungsverfahren und ihre medizinische Anwendung |
EP0097039A1 (de) * | 1982-06-16 | 1983-12-28 | Beecham Group Plc | 5-(E-2-Halovinyl)-2'-deoxyuridin-Derivate, Verfahren zur Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Anwendung bei der Behandlung von viralen Infektionen |
HU187736B (en) * | 1982-08-04 | 1986-02-28 | Mta Koezponti Kemiai Kutato Intezet,Hu | Process for producing /e/ -5-/2-bromovinyl/-2-comma above-deoxyuridine and o-acyl derivatives |
FI832884A (fi) * | 1982-08-17 | 1984-02-18 | Sandoz Ag | Desoxiuridinderivat, deras framstaellningsfoerfaranden och anvaendning som farmaceutiska medel |
ZA836902B (en) * | 1982-09-17 | 1985-05-29 | Glaxo Group Ltd | 5-halovinyl-2'-deoxyuridine derivatives |
EP0104857A1 (de) * | 1982-09-28 | 1984-04-04 | Beecham Group Plc | Deoxyuridin-Derivate, Verfahren zu deren Herstellung und ihre Verwendung in der Medizin |
US4658044A (en) * | 1983-09-16 | 1987-04-14 | Glaxo Group Limited | Intermediates for uracil derivatives |
EP0195805A4 (de) * | 1984-09-24 | 1987-07-09 | Scm Corp | Herstellung von 2-deoxyuridin. |
GB8517402D0 (en) * | 1985-07-10 | 1985-08-14 | Wellcome Found | Treatment of viral infections |
GB8629892D0 (en) * | 1986-12-15 | 1987-01-28 | Wellcome Found | Antiviral compounds |
US5215971A (en) * | 1986-12-19 | 1993-06-01 | Medivir Ab | Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides |
SE8605503D0 (sv) * | 1986-12-19 | 1986-12-19 | Astra Laekemedel Ab | Novel medicinal use |
US4863927A (en) * | 1987-05-11 | 1989-09-05 | Merck & Co., Inc. | 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils |
JPH0217199A (ja) * | 1988-07-05 | 1990-01-22 | Japan Tobacco Inc | 2’−デオキシ−β−アデノシンの製造方法 |
JPH0217198A (ja) * | 1988-07-05 | 1990-01-22 | Japan Tobacco Inc | 2’−デオキシ−β−シチジン誘導体およびその塩の製造法 |
WO1990001324A1 (en) * | 1988-08-10 | 1990-02-22 | Stephen Leslie Sacks | PRODUCTION OF RADIOIODINATED 1-β-D-ARABINOFURANOSYL)-5(E)-(2-IODOVINYL)URACIL, AND USES THEREOF, AND RELATED ANALOGUES INCORPORATING ALTERNATIVE HALOGEN RADIONUCLIDES, THE GENERAL RADIOHALOGENATION PRECURSORS, 1-(2,3,5-TRI-O-ACETYL-β-D-ARABINOFURANOSYL)-5(Z and E)-(2-TRIMETHYLSILYLVINYL)URACIL, PROCESSES FOR RADIOHA |
EA005497B1 (ru) * | 2001-01-03 | 2005-02-24 | Берлин Хеми Аг | Применение фармацевтической композиции, содержащей бривудин, для лечения герпесвирусных инфекций |
DE10109657A1 (de) * | 2001-02-28 | 2002-09-05 | Menarini Ricerche Spa | Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin |
JP4651942B2 (ja) * | 2001-12-20 | 2011-03-16 | フアーマセツト・インコーポレイテッド | Ebv及びkhsv感染並びにそれに伴う異常細胞増殖の治療 |
CN102432655A (zh) * | 2011-10-28 | 2012-05-02 | 河南师范大学 | 一种合成5-((e)-2-溴乙烯基)-2′-脱氧尿嘧啶核苷(溴呋啶)的方法 |
EP3792271A1 (de) | 2019-09-13 | 2021-03-17 | Aurobindo Pharma Limited | Verfahren zur herstellung von brivudin |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH541566A (de) | 1969-04-11 | 1973-09-15 | Schering Ag | Verfahren zur Herstellung von Nucleosiden |
DE2012888C3 (de) | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
DE2122991C2 (de) | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden |
US4093716A (en) | 1977-04-28 | 1978-06-06 | Research Corporation | Compositions containing 5-amino-5-deoxythymidine and pharmaceutically acceptable salts thereof |
US4093715A (en) | 1977-04-28 | 1978-06-06 | Research Corporation | 5-Iodo-5'-amino-2',5'-dideoxycytidine and the pharmaceutically acceptable salts thereof |
DE2721466A1 (de) | 1977-05-12 | 1978-11-16 | Robugen Gmbh | Verfahren zur herstellung von 2'-desoxyribofuranosylnucleosiden |
-
1978
- 1978-04-24 GB GB16158/78A patent/GB1601020A/en not_active Expired
-
1979
- 1979-04-14 DE DE19792915254 patent/DE2915254A1/de active Granted
- 1979-04-18 NL NL7903029A patent/NL192793C/nl not_active IP Right Cessation
- 1979-04-19 CH CH367179A patent/CH643273A5/de not_active IP Right Cessation
- 1979-04-23 FR FR7910230A patent/FR2432526A1/fr active Granted
- 1979-04-23 CA CA000326164A patent/CA1117108A/en not_active Expired
- 1979-04-23 SE SE7903541A patent/SE445832B/sv not_active IP Right Cessation
- 1979-04-23 IT IT09403/79A patent/IT1165954B/it active
- 1979-04-23 BE BE1/9368A patent/BE875773A/xx not_active IP Right Cessation
- 1979-04-24 JP JP5133379A patent/JPS554364A/ja active Granted
-
1981
- 1981-12-21 US US06/332,757 patent/US4424211A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
FR2432526A1 (fr) | 1980-02-29 |
SE7903541L (sv) | 1979-10-25 |
GB1601020A (en) | 1981-10-21 |
BE875773A (nl) | 1979-10-23 |
JPS642599B2 (de) | 1989-01-18 |
CA1117108A (en) | 1982-01-26 |
NL192793C (nl) | 1998-02-03 |
IT7909403A0 (it) | 1979-04-23 |
NL192793B (nl) | 1997-10-01 |
JPS554364A (en) | 1980-01-12 |
CH643273A5 (de) | 1984-05-30 |
IT1165954B (it) | 1987-04-29 |
FR2432526B1 (de) | 1982-10-08 |
US4424211A (en) | 1984-01-03 |
DE2915254A1 (de) | 1979-11-15 |
NL7903029A (nl) | 1979-10-26 |
SE445832B (sv) | 1986-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2915254C2 (de) | ||
EP0484333B1 (de) | Nucleosid-derivate und deren verwendung als arzneimittel | |
DE3036131C2 (de) | ||
DE2923368C2 (de) | ||
CH676712A5 (de) | ||
DE2409654A1 (de) | Therapeutisches mittel | |
DE3390162T1 (de) | Desoxyuridinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Pharmazeutika | |
DD255351A5 (de) | Verfahren zur herstellung von carbocyclischen purinnucleosiden | |
DE3508356C2 (de) | ||
EP0255894B1 (de) | Pyrimidinderivate, deren Herstellung und Arzneimittel, die diese Derivate enthalten | |
DE2833986C2 (de) | ||
US4383990A (en) | Antiviral agents, their preparation and use | |
DE3627024A1 (de) | In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine | |
CH653340A5 (de) | (e)-5-(2-bromvinyl)-uridine und verfahren zu ihrer herstellung. | |
EP0256400A2 (de) | Pyrimidinderivate, ihre Herstellung und Medikamente die diese Derivate enthalten | |
DE69034209T2 (de) | 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel | |
DE1620185C3 (de) | 5-Äthyl- und 5-Propyl-2'-deoxyuridin, Verfahren zur Herstellung dieser Verbindungen und diese Verbindungen enthaltende Arzneimittel | |
DE3820588C2 (de) | ||
EP0139859B1 (de) | 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
CH639373A5 (de) | N-alkenylmoranolin derivate. | |
DE3317702C2 (de) | ||
DE2511829C2 (de) | ||
DE2648239C3 (de) | Di-(trialkylstannyl)-pyrimidinderivate, Verfahren zu ihrer Herstellung und Verfahren zu ihrer Weiterverarbeitung zu nucleosidartigen Pyrimidinderivaten | |
CH649303A5 (de) | 5-niedrigalkyl-2'-desoxyuridin-5'-monophosphate, verfahren zu deren herstellung und diese verbindungen enthaltende antivirale mittel. | |
EP0105393B1 (de) | Neue Nucleosidverbindungen, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
8128 | New person/name/address of the agent |
Representative=s name: SCHOENWALD, K., DR.-ING. VON KREISLER, A., DIPL.-C |
|
D2 | Grant after examination | ||
8364 | No opposition during term of opposition | ||
V448 | Application of spc |
Free format text: PRODUCT NAME: E-5-(2-BROMVINYL)-2`-DESOXYURIDIN BRIVUDIN; REGISTRATION NO/DATE: 15/04/556, 19900423 Spc suppl protection certif: 193 75 022 Filing date: 19930514 |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: BERLIN - CHEMIE AG, 12489 BERLIN, DE |
|
V457 | Spc granted |
Free format text: PRODUCT NAME: E-5-(2-BROMVINYL)-2`-DESOXYURIDIN BRIVUDIN; REGISTRATION NO/DATE: 15/04/556, 19900423 Spc suppl protection certif: 193 75 022 Filing date: 19930514 |
|
V464 | Spc expired |
Free format text: PRODUCT NAME: E-5-(2-BROMVINYL)-2`-DESOXYURIDIN BRIVUDIN; REGISTRATION NO/DATE: 15/04/556, 19900423 Spc suppl protection certif: 193 75 022 Filing date: 19930514 |